Share this

Annual General Meeting 2018

The Annual General Meeting (AGM) in Swedish Orphan Biovitrum AB (publ) was held on Wednesday May 9 at 3.00 p.m. at Näringslivets Hus, Storgatan 19, Stockholm, Sweden.

CEO’s presentation at the AGM

The slides from CEO Guido Oelkers’ presentation at the AGM is available to download under “Related Documents” on this page.  

The AGM voted in favour of the resolutions proposed at the meeting, including:

Adoption of the profit and loss statements and balance sheet and discharge of liability 

The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits of SEK 4,486,594,396.

The board members and the chief executive officers were discharged from liability for the financial year 2017.

Election of Board of Directors, remuneration to the Directors and election of Auditor 

The ordinary board members Håkan Björklund, Annette Clancy, Matthew Gantz, Lennart Johansson, Helena Saxon and Hans GCP Shikan were re-elected and David Allsop and Elisabeth Svanberg were elected as new board members for the period until the end of the next AGM. Håkan Björklund was re-elected chairman of the Board.

The AGM approved the compensation to the Board in accordance with the nomination committee’s proposal.

Ernst & Young AB was re-elected as auditor of Sobi for the period until the end of the next AGM.

Principles for remuneration for the management, long-term incentive program, authorisation for the Board of Directors to resolve on the issuance of new shares and/or convertible bonds and/or warrants, and transfer of own shares 

The AGM approved the guidelines for remuneration for the management proposed by the Board.

The AGM also approved the Board’s proposal regarding the implementation of a long-term incentive program, and hedging arrangements in respect of the program including a directed issue of no more than 814,409 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 1,427,269 own common shares to program participants.

The AGM also approved the Board’s proposal regarding the approval to authorise the Board to resolve on the issuance of new shares and/or convertible bonds and/or warrants. The number of shares that may be issued, the number of shares that convertible bonds may be converted into and the number of shares that may be subscribed for by the exercise of warrants, may not exceed 30,000,000 shares in total.

The Board’s proposal regarding transfer of no more than 144,808 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Share Program 2015, was also approved by the AGM.

For full details on each proposal adopted by the AGM, please refer to “Related Documents” on this page.